Biohaven (BHVN) reported a Q4 non-GAAP net loss of $1.71 per share, wider than its loss of $1.61 a year earlier.
Analysts polled by FactSet expected a loss of $1.49.
The company did not report any revenue for the quarter ended Dec. 31.
As of Dec. 31, the company said it had about $489 million in cash, cash equivalents, marketable securities and restricted cash.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.